Caladrius Biosciences and Cend Therapeutics Announce Poster Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
May 26, 2022 08:00 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J. and SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to...
Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction
May 23, 2022 16:05 ET
|
Caladrius Biosciences, Inc.
Interim analysis to be conducted following enrollment suspension in the double-blind, randomized, placebo-controlled clinical trial Next development steps for XOWNA® to be announced by year-end 2022...
Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease
May 19, 2022 08:00 ET
|
Caladrius Biosciences, Inc.
Independent Data Monitoring Committee advises continuation of trial without modification No safety or tolerability concerns observed in the first two patients dosed Top-line data from all subjects...
Caladrius Biosciences to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 08:00 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
May 05, 2022 16:05 ET
|
Caladrius Biosciences, Inc.
Signs definitive merger agreement with Cend Therapeutics along with immediate investment and collaboration agreements Maintains strong financial position while advancing and expanding development...
Caladrius Biosciences to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022, at 4:30 p.m. Eastern Time
April 28, 2022 08:00 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences and Cend Therapeutics Announce Definitive Merger Agreement
April 27, 2022 07:00 ET
|
Caladrius Biosciences, Inc.
Combined company to be renamed Lisata Therapeutics upon transaction closing Combination will create a financially sound Nasdaq-listed company with a diverse product development pipeline, strong...
Caladrius Biosciences Treats First Patient in the Phase 1b Trial of CLBS201 for the Treatment of Diabetic Kidney Disease
April 12, 2022 08:00 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 22, 2022 16:05 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...
Caladrius Biosciences to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 22, 2022, at 4:30 p.m. Eastern Time
March 15, 2022 08:00 ET
|
Caladrius Biosciences, Inc.
BASKING RIDGE, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the...